Five-year survival rate from triple-negative breast cancer varies on follow up, platin agents and multidisciplinary team: a prospective analysis at tertiary level hospitals in Bangladesh
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253572Keywords:
MDT, Neoadjuvant chemotherapy, Platinum-based chemotherapy, Survival outcomes, Triple-negative breast cancerAbstract
Background: Triple-Negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer lacking ER, PR, and HER2, with high recurrence and mortality. This study evaluates survival outcomes and treatment impact in Bangladesh. The objective of this study was to assess the five-year survival rate of TNBC patients in Bangladesh, evaluate the impact of platin-based chemotherapy and MDT, and compare the outcomes of neoadjuvant and adjuvant treatments.
Methods: This prospective analysis was conducted on 165 TNBC patients from a cohort of 1672 breast cancer patients treated at two tertiary hospitals in Dhaka between January and December 2018. Patient data were collected prospectively, and follow-up was conducted every six months via phone or departmental database. Data on demographic characteristics, co-morbidities, treatment regimens, and survival outcomes were analyzed.
Results: Among the 165 TNBC patients, 37 (22.42%) died within the five-year follow-up period, with 52 (58.43%) surviving. Disease-Free Survival (DFS) was observed in 47 (52.81%) patients, and recurrence was recorded in 5 (5.62%). The survival rate varied significantly across different age groups: 59.62% survival in the 40-63 years age group, 32.69% in the 39 and younger group, and 7.70% in the 64 and above group. Notably, 91 (55.15%) patients received neoadjuvant chemotherapy (NACT), and 74.74% of them survived five years. The overall survival (OS) rate was highest in those treated with platinum-based agents, with a survival rate of 70.97%. The median survival time for those receiving MDT was 61.07%, compared to 19.79% for those treated without MDT. A significant correlation was found between treatment completion (p<0.05), chemotherapy regimen (p<0.01), and follow-up adherence (p<0.05) on survival outcomes.
Conclusions: This study highlights the importance of early detection, treatment completion, and MDT management in improving TNBC survival, particularly for those under 63 years.
Metrics
References
Lawrence RT, Perez EM, Hernández D, Miller CP, Haas KM, Irie HY, et al. The proteomic landscape of triple-negative breast cancer. Cell Rep. 2015;11(4):630-44. DOI: https://doi.org/10.1016/j.celrep.2015.03.050
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. DOI: https://doi.org/10.1371/journal.pone.0157368
Poggio F, Bruzzone M, Ceppi M, Pondé NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497-1508. DOI: https://doi.org/10.1093/annonc/mdy127
Jin J, Zhang W, Ji W, Yang F, Guan X. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther. 2017;18(6):369-378. DOI: https://doi.org/10.1080/15384047.2017.1323582
Prades J, Remue E, van Hoof E, Borras JM. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy. 2015;119(4):464-74. DOI: https://doi.org/10.1016/j.healthpol.2014.09.006
Shen MC, Massarweh NN, Lari SA, Vaporciyan AA, Selber JC, Mittendorf EA, et al. Clinical course of breast cancer patients with isolated sternal and full-thickness chest wall recurrences treated with and without radical surgery. Ann Surg Oncol. 2013;20(13):4153-60. DOI: https://doi.org/10.1245/s10434-013-3202-4
El Zein D, Hughes M, Kumar S, Peng X, Oyasiji T, Jabbour H, et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature. Clin Breast Cancer. 2017;17(5):382-391. DOI: https://doi.org/10.1016/j.clbc.2017.04.009
Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169-80. DOI: https://doi.org/10.1016/S1470-2045(17)30891-4
Kumar D, Haldar S, Gorain M, Kumar S, Mulani FA, Yadav AS, et al. Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway. BMC Cancer. 2018;18(1):52. DOI: https://doi.org/10.1186/s12885-017-3876-2
Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(10):1385-93. DOI: https://doi.org/10.1016/S1470-2045(18)30380-2
Droog E, Armstrong C, MacCurtain S. Supporting patients during their breast cancer journey: the informational role of clinical nurse specialists. Cancer Nurs. 2014;37(6):429-35. DOI: https://doi.org/10.1097/NCC.0000000000000109
Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z. Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis. Oncol Lett. 2015;9(6):2825-32. DOI: https://doi.org/10.3892/ol.2015.3072
Rosenberg SM, Partridge AH. Management of breast cancer in very young women. Breast. 2015;24 (Suppl 2):S154-8. DOI: https://doi.org/10.1016/j.breast.2015.07.036
Reddy P, Ebrahim S, Singh B, Ramklass S, Buccimazza I. Breast Cancer and HIV: a South African perspective and a critical review of the literature. S Afr J Surg. 2017;55(1):10-5.
Cabrera-Galeana P, Soto-Perez-de-Celis E, Reynoso-Noverón N, Villarreal-Garza C, Arce-Salinas C, Matus-Santos J, et al. Clinical characteristics and outcomes of older women with breast cancer in Mexico. J Geriatr Oncol. 2018;9(6):620-625. DOI: https://doi.org/10.1016/j.jgo.2018.04.003
Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016;66(1):43-73. DOI: https://doi.org/10.3322/caac.21319
Morishima T, Matsumoto Y, Koeda N, Shimada H, Maruhama T, Matsuki D, et al. Impact of comorbidities on survival in gastric, colorectal, and lung cancer patients. J Epidemiol. 2019;29(3):110-5. DOI: https://doi.org/10.2188/jea.JE20170241
Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, et al. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(2):223-32. DOI: https://doi.org/10.1007/s10549-014-2876-z
Kaya V, Yildirim M, Yazici G, Gunduz S, Bozcuk H, Paydas S. Effectiveness of platinum-based treatment for triple negative metastatic breast cancer: a meta-analysis. Asian Pac J Cancer Prev. 2018;19(5):1169-73.
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108-21. DOI: https://doi.org/10.1056/NEJMoa1809615
Newman LA, Kaljee LM. Health disparities and triple-negative breast cancer in African American women: a review. JAMA Surg. 2017;152(5):485-93. DOI: https://doi.org/10.1001/jamasurg.2017.0005
Downloads
Published
How to Cite
Issue
Section
